Joshua Lin and Team: New Evidence on Long-Term Anticoagulation for Unprovoked VTE
Joshua Lin, Executive Director of Mass General Brigham Center for Integrated Healthcare Data Research, posted on LinkedIn:
”New Evidence on Long-Term Anticoagulation for Unprovoked VTE
We are pleased to share our recent BMJ publication demonstrating that continuation of oral anticoagulant therapy beyond the initial 90-day treatment period after a first unprovoked venous thromboembolism (VTE) is associated with a significantly lower risk of recurrent thrombosis and all-cause mortality, compared with early discontinuation. Extended therapy, however, is also associated with a higher risk of major bleeding – underscoring the importance of individualized clinical decision-making.
Full study here.
Press Release here.”
Title: Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation
Authors: Kueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, Yichi Zhang, Alexander Cervone, Anna R Kehoe, Katsiaryna Bykov
Stay updated with Hemostasis Today.
-
May 9, 2026, 23:50Manuel Carbonell: Modern Phlebology Should Not Be a Competition of Devices and Technology
-
May 9, 2026, 23:37Maia Meier’s Journey: Raising Awareness for Women Living Without a Diagnosis – European Haemophilia Consortium
-
May 9, 2026, 23:13Aakanksha Angra: Building a Community for Advances in ALL
-
May 9, 2026, 22:55Romiplostim Versus Placebo in the Management of Chemotherapy-Induced Thrombocytopenia – Transfusion Evidence Library
-
May 9, 2026, 22:43Simon Ash: Gestational Thrombocytopenia and Maternal Risk at SOAPAM 2026
-
May 9, 2026, 22:18Rupam Manna: Thrombocytopenia in Oncology – Complete High-Yield Guide for Safe Chemotherapy Delivery
-
May 9, 2026, 22:12Muhammad Aasim Ali: Treatment Strategies for Chemotherapy-Induced Cytopenias
-
May 9, 2026, 16:38Joseph R. Shaw: Risk Stratification is Only Useful if It is Practical, Consistent, and Easy to Apply at the Bedside
-
May 9, 2026, 16:11Milad Abdalla: When 180,000 Becomes 45,000 – The EDTA Trap